In a recent academic session, Professor David F. McDermott from Beth Israel Deaconess Medical Center presented the latest findings from Part 1 of the LITESPARK-024 study. This trial evaluated the safety and preliminary efficacy of the HIF-2α inhibitor belzutifan in combination with the CDK4/6 inhibitor palbociclib in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC).

At a recent international academic conference, Professor Chad Tang from The University of Texas MD Anderson Cancer Center presented pioneering research on circulating Kidney Injury Molecule-1 (KIM-1) and circulating tumor DNA (ctDNA) as prognostic markers for oligometastatic clear cell renal cell carcinoma (ccRCC). During the session, he officially introduced the K-COMPAsS model.

At a recent academic conference, Professor Ben Tran from the Peter MacCallum Cancer Centre and the University of Melbourne presented the preliminary results of the CLIMATE study (ANZUP 1906). This prospective cohort study aimed to evaluate the clinical utility of microRNA-371a-3p (miR-371) as a marker for minimal residual disease (MRD) in predicting relapse in patients with clinical stage 1 (CS1) testicular germ cell tumors (TGCTs).

At a recent international oncology academic conference, Professor Avivit Peer presented the latest findings from the KEYMAKER-U04 Substudy 04B. This study investigated the efficacy and safety of adding an anti-LAG-3 or anti-TIGIT antibody to the standard-of-care enfortumab vedotin (EV) plus pembrolizumab backbone as a first-line treatment for advanced urothelial carcinoma (UC). Our editorial team has summarized the core academic content for our readers.

At a recent international academic symposium, Dr. Aly-Khan A. Lalani from McMaster University presented the primary results of the CYTOSHRiNk study (Abstract 416). This randomized Phase II trial evaluated the efficacy and safety of cytoreductive stereotactic body radiotherapy (SBRT) combined with nivolumab plus ipilimumab (Nivo+Ipi) in patients with treatment-naïve metastatic clear cell renal cell carcinoma (mRCC).

With the continuous increase in the global incidence of prostate cancer and the variation in disease progression risk driven by tumor heterogeneity, accurate risk stratification is crucial for optimizing clinical treatment decisions. At a recent international oncology conference, Dr. Anna Clare Wilkins from The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust delivered a special presentation on the "External validation of a digital pathology-based multimodal artificial intelligence (MMAI) derived prognostic biomarker in the randomized phase III CHHiP trial" (Abstract 308). This study confirmed that MMAI can overcome the limitations of traditional clinicopathological models, significantly improving the predictive accuracy of survival endpoints in patients with localized prostate cancer. Our editorial team has compiled the core highlights of this presentation for our readers.

Editor’s Note: Dr. Enrique Gallardo from Parc Taulí University Hospital (Autonomous University of Barcelona) presented the final overall survival (OS) results of the phase 3 EORTC 1333/PEACE III trial (Abstract…

At a recent major oncology conference, Professor Fred Saad from the University of Montreal Hospital Center delivered an oral presentation on the latest findings of the PANTHER study (Abstract 19). This study reported the first-in-human phase 1 dose-escalation results of a novel PSMA-targeted radioligand therapy (RLT)—Actinium-225-PSMA-trillium (225Ac-PSMA-trillium)—in patients with metastatic castration-resistant prostate cancer (mCRPC), bringing a new treatment strategy and hope to heavily pretreated patients.

At a recent major oncology conference, Professor Johann de Bono from the Royal Marsden Hospital presented Abstract 17, detailing the preliminary results of a first-in-human Phase 1 dose-escalation trial. The study evaluated VAR5500, a dual-masked pro-X10 T-cell engager targeting PSMA and CD3, in patients with metastatic castration-resistant prostate cancer (mCRPC). This study provides critical proof-of-concept data for the next generation of precision immunotherapy in solid tumors.

At the recent oncology conference, Dr. Amar Kishan, Radiation Oncologist at the University of California, Los Angeles (UCLA), presented Abstract 305, a highly anticipated individual patient data (IPD) meta-analysis addressing the optimal patient selection and duration for hormone therapy (HT) combined with post-operative radiotherapy (RT) in recurrent prostate cancer.